NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that its data will be ...
– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product’s performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue ...
NASHVILLE, Tenn., Jan. 13, 2026 /PRNewswire/ -- Revance and Teoxane announce the FDA approval of RHA ® Dynamic Volume from the Teoxane RHA ® Collection for cheek augmentation and/or the correction of ...
According to the terms of the deal, Crown will buy Revance at $3.65 per share At the closing, Revance will no longer trade on the Nasdaq Revance’s portfolio includes Daxxify for injection and the RHA ...
We’re back again at AUSTEX Wellness & Medical Spa in Lakeway! We spoke with Laurel Belfiore, Founder & Owner, about dermal fillers which are a great anti-aging tool, but a lot of people are hesitant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results